Comparison of intestinal metaplasia and Helicobacter pylori scores in patients undergoing upper gastrointestinal endoscopy

Year 2018, Volume: 43 Issue: 3, 574 - 580, 30.09.2018

Uğur Kesici

https://doi.org/10.17826/cumj.338949

Cited By: 2

Abstract

Purpose: The aim of this study is toreveal the relationship between Helicobacter pylori (HP) and intestinal metaplasia (IM) in patients with upper gastrointestinal endoscopy due to dissipative complaints.

Materials and Methods: Patients aged 15-84 years who underwent upper gastrointestinal endoscopy were included in this study. Demographically age and sex of the patients and histopathologically IM and HP scores were recorded. Patients were divided into two groups, Group A and Group B, aged 15-49 and over 50 years old respectively. It was investigated whether there was correlation between IM and HP scores with regards to several variables.

Results: This study included 200 patients aged 15-84 years. In Group B patients, IM incidence was significantly higher. In HP negative patients; IM rate in patients in Group B was significantly higher than Group A. In male patients in Group B, IMS mild to moderate incidence was statistically significantly higher.

Conclusion: There are studies in the literature that show that there is a significant relationship between HP positivity and IM development, as well as studies that suggest that there is no significant relationship between HP positivity and IM development consistent with our study. The most important risk factor for the development of IM in our study was male sex above 50 years.

Keywords

Endoscopy, gastrointestinal system, intestinal metaplasia, helicobacter pylori.

Üst gastrointestinal sistem endoskopisi yapılan hastalarda intestinal metaplazi ve Helikobakter pylori skorlarının karşılaştırılması

Abstract

Amaç: Bu çalışmada dispeptik yakınmaları nedeniyle üst gastrointestinal system (GİS) endoskopisi yapılan hastalarda helicobacter pylori (HP) ile intestinal metaplazi (İM) arasındaki ilişkinin ortaya konulması amaçlanmıştır. 

Gereç ve Yönetim: Bu çalışmaya üst GİS endoskopisi yapılan 15-84 yaş arası hastalar dahil edildi. Hastaların demografik olarak yaş ve cinsiyetleri ile histopatolojik olarak İM ve HP skorları kaydedildi. Hastalar 15-49 yaş arası ve 50 yaş üstü olmak üzere sırasıyla Grup A ve Grup B olmak üzere iki gruba ayrıldı. İM ve HP skorları arasında çeşitli değişkenlere göre korelasyon olup olmadığı araştırıldı.

Bulgular: Bu çalışmaya 15-84 yaş arası 200 hasta dahil edildi. Grup B’deki hastalarda IM görülme oranı istatiksel olarak anlamlı düzeyde yüksekti. HP negatif olan hastalarda ise; Grup B’deki hastalarda IM oranı, Grup A’ya göre anlamlı olarak yüksekti. Grup B’deki erkek hastalarda IMS hafif ve orta görülme oranı istatiksel olarak anlamlı düzeyde yüksekti.

Sonuç: Literatürde HP pozitifliği ile İM gelişimi arasında anlamlı bir ilişki olduğunu gösteren çalışmaların yanısıra bu çalışmamızla uyumlu olarak HP pozitifliği ile İM gelişimi arasında anlamlı bir ilişki olmadığını bildiren çalışmalar da bulunmaktadır. Çalışmamızda İM gelişimi için en önemli risk faktörünün 50 yaş üzeri erkek cinsiyet olduğu sonucuna varılmıştır. 

Keywords

Endoskopi, gastrointestinal sistem, intestinal metaplazi, helicobacter pylori

References

• 1. © Copyright World Health Organization (WHO), 2017. All Rights Reserved.
• 2. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:609-16.
• 3. Özer Etik D, Turhan N. Gastrik İntestinal Metaplaziye Gastroenterolog ve Patolog Gözü ile Bakış. Güncel Gastroenteroloji. 2016;20:375-82.
• 4. Sugimoto M, Ban H, Ichikawa H, Sahara S, Otsuka T, Inatomi O, Bamba S, Furuta T, Andoh A. Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer. Intern Med. 2017;56:579-86.
• 5. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 61: 646-64, 2012.
• 6. Uemura N, Okamoto S, Yamamoto S, et al.Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-9, 2001.
• 7. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet 2: 58-60, 1975.
• 8. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 113: 1983-91, 1997.
• 9. Silva E, Teixeria A, David L et al. Mucins as key molecules for the classification of intestinal metaplasia. Mod Pathol 2004;17:62-74.
• 10. Correa P, Piazuela MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010;105:493-8.
• 11. Gonzales CA, Sans-Anquela JM, Gisbert JB, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. a review of th evidence. Int J Cancer2013;133:1-12.
• 12. Yoon H, Kim N. Diagnosis and management of the high risk group for gastric cancer. Gut Liver 2015; 9:5-17.
• 13. Conteduca V, Sansonna D, Lauleta G et al. H Pylori infection and gastric cancer: state of the art. Int J Oncology 2013;42:5-18.
• 14. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004 Jan 14;291(2):187-94.
• 15. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151:121-8.
• 16. Kodama M, Murakami K, Okimoto T, Abe T, Nakagawa Y, Mizukami K, Uchida M, Inoue K, Fujioka T. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion. 2012;85:126-30.
• 17. Kang JM, Kim N, Shin CM, Lee HS, Lee DH, Jung HC, Song IS. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication: a three-year follow-up study in Korea. Helicobacter. 2012;17:86-95.
• 18. Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011;83:253-60.
• 19. Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GN. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum. Gut. 1992;33:16-20.
• 20. Ajdarkosh H, Sohrabi M, Moradniani M, Rakhshani N, Sotodeh M, Hemmasi G, Khoonsari M, Ameli M, Malekzadeh R, Zamani F. Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors. Eur J Cancer Prev. 2015 ;24:400-6.
• 21. Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30(4):414-423.
• 22. Topal D, Göral V, Yılmaz F. Helicobacter pylori’nin intestinal metaplazi, gastrik atrofi ve Bcl-2 ile ilişkisi. Turkiye Klinikleri J Gastroenterohepatol 2004, 15:65-73.